研究报告 Research Report 9 Jun 2025 信达生物 Innovent Biologics (1801 HK) 2025 ASCO 数据超预期，创新潜力不断兑现 2025 ASCO Data Beats Expectations, Validating Sustained Innovation Execution [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$73.15 目标价 HK$90.10 HTI ESG 3.6-1.4-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$120.81bn / US$15.40bn 日交易额 (3 个月均值) US$146.21mn 发行股票数目 1,652mn 自由流通股 (%) 93% 1 年股价最高最低值 HK$74.25-HK$30.00 注：现价 HK$73.15 为 2025 年 06 月 06 ...

Financial Data and Key Metrics Changes - The company ended Q1 2025 with a consolidated cash balance of $18.5 million, down from $40.4 million at the end of 2024 [23] - Cash used in operations for Q1 2025 was $25.6 million, reduced from $38.2 million for the same period in 2024 [23] - Revenue for Q1 2025 was $24.1 million, compared to $28 million in Q1 2024, with a net loss of $26.4 million or $1.03 per share, down from a net loss of $63.5 million or $3.04 per share in Q1 2024 [23] Business Line Data and Key Metrics Changes - The company is focusing on operational efficiencies to cut annualized operational cash burn to below $50 million in the second half of 2025 [20] - Four formal near-term transaction proposals have been received, including a facility sale and significant equity investment, aimed at strengthening the balance sheet [21][22] Market Data and Key Metrics Changes - Colorectal cancer incidences have doubled in U.S. adults aged 55 from 1995 to 2019, with projections indicating it will become the leading cause of cancer-related death in men by 2030 [7][8] - The company is addressing the urgent need for alternative treatments for colorectal cancer, particularly for younger patients who are increasingly affected [7][8] Company Strategy and Development Direction - The company is pursuing a Type B meeting with the FDA to discuss the potential accelerated approval of its product, BotBal, based on data from over 1,200 patients [25] - The new leadership, including Dr. Richard Goldberg, is expected to enhance the company's regulatory strategy and development focus on colorectal cancer and other solid tumors [15][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the new regulatory environment under the current administration, which is expected to favor rapid approval of transformative therapies [10][11] - The company is committed to delivering meaningful treatments for patients, particularly in light of the increasing prevalence of colorectal cancer among younger demographics [19][20] Other Important Information - The company has received proposals for significant equity investments at a premium to the current share price, which could materially strengthen its financial position [21][22] - The company is also exploring licensing agreements that could provide upfront cash and royalties, further supporting its operational needs [59] Q&A Session Summary Question: What is the status of the Phase II study and overall survival endpoint? - Management indicated that they have approximately one more year of data from both Phase I and Phase II studies, with significant follow-up indicating potential survival benefits [31][34] Question: Are there any updates on the development plan in light of recent data? - The focus remains on colorectal cancer, particularly in refractory disease and the neoadjuvant setting, with plans to present data at an upcoming conference [46][47] Question: What is the strategy for sharing Phase II data with the market? - Management is open to sharing Phase II data in conjunction with the FDA meeting, emphasizing the importance of demonstrating safety and efficacy [72]